ArticleBMC psychiatry2025
Prevalence and related factors of comorbid suicide attempts and psychotic symptoms in first-episode drug-naïve patients with major depressive disorder.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictive value of antioxidant and thyroid function indicators for non-suicidal self-injury in adolescents with major depressive disorder.Frontiers in psychiatry · 2026Article
- Metabolic risk stratification and psychotic symptoms in first-episode drug-naïve major depressive disorder: a principal component-based cross-sectional study.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsychotic symptoms (PS) and suicide attempts (SA) are especially prevalent in individuals with major depressive disorder (MDD) and serve as key indicators of worsening condition and poor prognosis. This study examined the occurrence of comorbid suicide attempts and psychiatric symptoms (SAPS) in MDD patients, along with the factors associated with these conditions.
methodsOne thousand seven hundred eighteen first-episode drug-naïve (FEDN) MDD patients were involved in this study, and data on their sociodemographic traits, clinical symptom evaluations, and specific biochemical markers were gathered. Patients were categorised into different clinical subgroups based on the presence of SAPS and were analyzed comparatively.
resultsAbout 4.4% of patients had both suicide attempts and psychotic symptoms. Compared to those without SAPS, these patients were older, had an earlier disease onset, and showed higher scores on depression (HAMD), anxiety (HAMA), and illness severity (CGI-SI). They also had different thyroid hormone levels. Higher HAMA (OR = 1.643, 95% CI: 1.439-1.878, p < 0.001), CGI-SI (OR = 8.359, 95% CI: 2.651-26.352, p < 0.001), and TSH levels (OR = 2.025, 95% CI: 1.652-2.842, p < 0.001) were strongly linked to SAPS. The AUCs for HAMA, CGI-S, and TSH were above 0.86, and the combined model yielded an AUC of 0.980.
conclusionThese findings highlight the importance of evaluating anxiety, illness severity, and thyroid function in identifying high-risk FEDN MDD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.